Multiple sclerosis is a chronic autoimmune condition of the central nervous system. The immune system attacks myelin, the protective sheath surrounding nerve fibres, disrupting the signals that travel between the brain, spinal cord, and the rest of the body. Over time, repeated episodes of inflammation cause demyelination and, in many patients, progressive axonal damage that leads to irreversible neurological deficit.

MS presents differently in different people. The most common form, relapsing-remitting MS (RRMS), involves episodes of worsening symptoms followed by partial or complete recovery. Secondary progressive MS (SPMS) develops in a significant proportion of RRMS patients over time, bringing steadily worsening disability without clear relapses. Primary progressive MS (PPMS) involves gradual deterioration from the outset, without distinct relapse episodes.

Common long-term consequences of MS include:

• Mobility difficulties; weakness, spasticity, and balance problems affecting walking and daily function
• Fatigue; one of the most disabling and least visible symptoms, affecting the majority of patients
• Cognitive impairment; problems with memory, processing speed, concentration, and word-finding
• Visual disturbances; including optic neuritis, blurred vision, and double vision
• Bladder and bowel dysfunction; urgency, frequency, and incontinence
• Chronic pain and sensory symptoms; numbness, tingling, burning sensations, and neuropathic pain
• Speech and swallowing difficulties; in more advanced disease
• Emotional and psychological impact; depression and anxiety are significantly more common in people with MS than in the general population

These challenges compound over time. Managing MS is not just about treating relapses, it is about preserving function, maintaining quality of life, and slowing the accumulation of disability over years and decades.

Disease-modifying therapies (DMTs) have changed the landscape of MS management considerably over the past three decades. For many patients, they reduce relapse frequency and delay progression. However, they carry well-recognised limitations:

The core limitation: No currently approved therapy reliably halts the progressive neurodegeneration that underlies long-term disability in MS, particularly in progressive forms of the disease. That unmet need, slowing neurodegeneration in progressive MS is what has kept MSC-based research moving forward.

Stem cell therapy for MS is based on a different principle than conventional disease-modifying treatment. Rather than targeting a single arm of the immune response, MSC therapy aims to recalibrate immune function more broadly, whilst also supporting the survival and repair of neural tissue. It is the subject of active clinical research, with published data from multiple centres and ongoing randomised trials.

The Science Behind Mesenchymal Stem Cells (MSCs)

GS Medical Services coordinates treatment at specialist clinics in Germany that use mesenchymal stem cells, multipotent cells derived from bone marrow, adipose tissue, or umbilical cord, with well-documented immunomodulatory and neuroprotective properties. In MS, MSCs may act through several distinct mechanisms:

• Immune recalibration: MSCs interact with multiple immune cell populations, suppressing the activity of autoreactive T-cells and B-cells that drive demyelination, promoting regulatory T-cell populations, and shifting the balance of macrophage activity from pro-inflammatory to reparative. Unlike broad immunosuppression, this effect is selective and does not leave patients broadly vulnerable to infection.
• Neuroprotection: MSCs secrete a range of neurotrophic factors that support the survival of neurons and oligodendrocytes (the cells responsible for myelin production) in the damaged central nervous system.
• Remyelination support: Some research suggests MSCs may promote oligodendrocyte precursor cell differentiation, supporting the regeneration of myelin around damaged axons. Whilst full remyelination remains an ambitious goal, even partial restoration of myelin integrity could translate into functional improvement in selected patients.
• Reduction of neuroinflammation: Chronic neuroinflammation is a major driver of progressive neurological damage in MS. MSCs can modulate microglia, the brain's resident immune cells, and reduce pro-inflammatory cytokine levels in the CNS, potentially slowing the rate of ongoing damage.
• Axonal protection: By reducing the inflammatory and oxidative environment in which axonal degeneration occurs, MSC therapy may slow the irreversible nerve damage that underlies progressive disability, particularly relevant in SPMS and PPMS, where neuroprotection is the primary unmet need.

Stem cell therapy for MS is not a cure. It does not reverse established neurological damage, and it does not guarantee stabilisation in every patient. Outcomes vary considerably depending on MS type, disease duration, degree of existing disability, and individual biological response. Patients with earlier-stage or relapsing disease tend to show more favourable responses than those with advanced progressive disease. This is discussed openly during every assessment.

A comprehensive cellular therapy programme is designed specifically for international and regional patients seeking high-standard neurological care. Every stage is carefully coordinated by our dedicated team.

Step 1: Comprehensive Medical Review and Eligibility Assessment

Your evaluation begins with a thorough review to determine whether stem cell therapy is appropriate for your specific condition:

• Review of recent neurological assessments and relapse history
• Expanded Disability Status Scale (EDSS) assessment and functional history
• Comprehensive medical history, including MS type, duration, prior DMTs, and response to each
• In-depth consultation with the medical team
• Honest, transparent assessment of whether you are a suitable candidate for cellular therapy

Step 2: Personalised Treatment Planning

If you are considered a suitable candidate, a fully individualised protocol is developed:

• Customised plan based on MS type, disease activity, disability level, treatment history, and overall health
• Clear explanation of the procedure, realistic outcome expectations, and treatment timeline
• Transparent discussion of potential benefits, risks, and alternative options
• Full logistics support, including travel arrangements and accommodation guidance for international patients

Step 3: Cellular Therapy Procedure

Treatment is conducted by experienced, licensed physicians in a clinical setting that meets German and international medical standards:

• Administered primarily via intravenous infusion; some protocols incorporate intrathecal administration depending on the clinical picture
• Outpatient basis; most patients return to their accommodation the same day
• Sterile clinical environment with full infection control protocols
• Physician-supervised throughout, with post-treatment monitoring before discharge
• The procedure typically takes 2-4 hours, including preparation and observation

Step 4: Structured Follow-Up and Progress Monitoring

Care continues well beyond the treatment procedure:

• Remote follow-up via secure telemedicine, eliminating the need for repeated international travel
• Personalised rehabilitation guidance to complement cellular therapy, including physiotherapy, cognitive rehabilitation, and fatigue management strategies
• Long-term monitoring to assess treatment durability and determine whether further intervention is warranted

Stem cell therapy is not appropriate for every person with MS. Based on current clinical evidence and our experience, individuals who may benefit most typically share the following characteristics:

• Confirmed MS diagnosis, relapsing-remitting, secondary progressive, or primary progressive, with documented neurological deficits
• Inadequate response to, intolerance of, or contraindications to one or more disease-modifying therapies
• Active or recently active disease
• EDSS score generally between 2.0 and 6.5; patients with very mild disability or very advanced disability require individual assessment
• Good general health outside of MS, without active serious infection, malignancy, or significant organ dysfunction
• Realistic understanding that the goal is to slow progression and reduce inflammatory activity, not to reverse established neurological damage
• Commitment to continuing appropriate neurological follow-up and rehabilitation alongside and after treatment

Patients with very advanced disability, rapidly progressing disease requiring urgent intervention, or significant comorbidities may not be suitable for this approach. Candidacy is assessed individually and communicated clearly.

The following are based on current clinical research and emerging patient outcomes. Outcomes are not guaranteed and vary from individual to individual.

• Reduced relapse frequency: A proportion of patients with relapsing MS report a reduction in relapse rate following MSC treatment, consistent with the immunomodulatory mechanism of action.
• Stabilisation of disability: In some patients, particularly those with active inflammatory disease, MSC therapy has been associated with a period of stabilisation of disability, halting or slowing the accumulation of further neurological deficits.
• Improved fatigue: Fatigue is among the most commonly reported improvements following MSC treatment in MS patients. Even where objective neurological measures show modest change, improvements in fatigue can translate into meaningful gains in daily functioning.
• Improved motor function: Some patients report improvements in limb strength, coordination, and walking ability, particularly those who still retain partial function in affected areas.
• Cognitive improvements: A proportion of patients note improvements in processing speed, concentration, and memory, outcomes that are difficult to achieve through conventional DMTs.
• Improved quality of life: Patient-reported quality-of-life measures, including the Multiple Sclerosis Impact Scale (MSIS-29), have shown improvements in published studies following MSC treatment. The field continues to evolve, and several larger trials are currently underway.

Research published in peer-reviewed medical journals, including data from European and international MS centres, has reported improvements in relapse rate, disability scores, and patient-reported outcomes following MSC therapy. The evidence base is growing, but remains in the research phase.

As with any medical procedure, there are potential risks, which are discussed in detail during your personalised consultation.

Common side effects (typically mild and temporary):

• Low-grade fever or flu-like symptoms in the 24-48 hours following infusion
• Mild fatigue on the day of treatment
• Transient headache
• Mild discomfort or bruising at the IV site
• Temporary increase in MS symptoms in the first 1-2 weeks, generally self-limiting and resolving within days

Rare but serious complications:

• Infection; rare when appropriate clinical protocols are followed
• Allergic or immune reaction to the cell preparation is uncommon with MSC preparations, which have low immunogenicity
• Thromboembolic events are very rare; carefully screened for during pre-treatment assessment

Serious complications are uncommon when the procedure is performed by experienced practitioners in a compliant clinical setting. All patients receive comprehensive pre-procedure screening, monitoring throughout the procedure, and clear post-procedure guidance.
Post-Treatment Guidance: All patients receive comprehensive post-treatment instructions, including activity recommendations, guidance on continuing or resuming DMTs where appropriate, warning signs requiring immediate attention, and strategies to optimise recovery through rehabilitation and lifestyle.

Choosing the right medical coordination partner matters, particularly when travelling abroad for treatment of a complex neurological condition. Here’s what we offer:

• German Clinical Excellence: Treatments are guided by the evidence-based protocols and clinical standards of Europe's leading centres for biological and regenerative medicine. Germany's regulatory framework for advanced therapies is among the most rigorous in the world.
• Compassionate and Expert Care: Our physicians and coordinators combine clinical knowledge with genuine commitment to patient wellbeing, ensuring you are fully informed and supported at every stage, from initial enquiry through to long-term follow-up.
• Personalised Treatment Plans: No two patients with MS present identically. Treatment protocols are built around your specific MS type, disease activity, disability profile, treatment history, and personal circumstances.
• International Patient Support: Dedicated coordination for patients travelling from across the UAE, Gulf region, and internationally, including appointment management, documentation, travel logistics, and accommodation guidance.
• Transparency and Honest Guidance: We provide clear, realistic information about candidacy, expected outcomes, and potential risks. We do not overstate what MSC therapy can offer, and we are direct when the evidence does not support treatment for a particular case.
• Continuity of Care: Through secure telemedicine, your relationship with our medical team continues long after you return home, with structured follow-up, objective monitoring, and ongoing guidance built into every programme.

If you or a family member is living with MS and seeking options beyond standard care, the first step is a thorough medical evaluation to determine whether regenerative treatment is appropriate for your specific situation. You may consult Dr. Med. Gerhard Siebenhüner for expert assessment and personalised treatment guidance.

Your initial consultation includes:

• Confidential review of your medical records and treatment history
• Honest assessment of whether you are a suitable candidate for cellular therapy
• Realistic discussion of potential benefits, risks, and expected outcomes for your specific MS type and stage
• Clear explanation of the treatment process, timeline, and logistics
• Transparent pricing with no hidden costs
• Time to ask questions and raise concerns, with no pressure to proceed

There is no obligation to go ahead with treatment following your consultation.

Is stem cell therapy suitable for all types of MS? 

MSC therapy has been explored across relapsing-remitting, secondary progressive, and primary progressive MS. Suitability is determined during consultation.

How long does the stem cell therapy procedure take?

The infusion typically takes 2-4 hours. Plan to spend 4-6 hours at the clinic on the treatment day, including preparation and post-procedure monitoring. Most patients return to their accommodation the same day.

Can I continue my current MS medication alongside stem cell therapy? 

This depends on the specific medication. Some DMTs are compatible with MSC therapy; others may require temporary adjustments during the treatment period.

How long after a diagnosis of MS can stem cell therapy be considered? 

There is no minimum time since diagnosis. What matters more is the current pattern of disease activity, the degree of disability, and the treatment history. 

Is stem cell therapy regulated in Germany? 

Yes. Stem cell therapies in Germany are subject to strict national and EU regulation. Treatment is performed in licensed clinical facilities under the supervision of a qualified physician following an individual medical assessment.

How much does treatment cost?

Costs depend on the treatment protocol, number of sessions, and individual clinical requirements. Full, transparent pricing is provided following a medical assessment. There are no hidden charges.

The information on this page is for educational and informational purposes only and should not be construed as medical advice. Stem cell therapy outcomes vary considerably between individuals, and treatment may not be suitable for everyone. Always consult a qualified medical professional before making decisions about your health.